Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy

American Journal of Physiology - Endocrinology and Metabolism

Volumn 290, Issue 1, 2006, Pages

  Monti, Lucilla D ^a   Setola, Emanuela ^a   Fragasso, Gabriele ^a   Camisasca, Riccardo P ^a   Lucotti, Pietro ^a   Galluccio, Elena ^a   Origgi, Anna ^a   Margonato, Alberto ^a   Piatti, PierMarco ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Endothelium; Insulin resistance

Indexed keywords

CITRIC ACID; CYCLIC GMP; ENDOTHELIN 1; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; GLUCOSE; INSULIN; PLACEBO; TRIMETAZIDINE; 3 HYDROXYBUTYRIC ACID; FATTY ACID;

ADULT; AGED; ARTICLE; CALORIMETRY; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FOREARM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART MUSCLE ISCHEMIA; HUMAN; LIPID OXIDATION; MALE; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN SECRETION; SKELETAL MUSCLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; LIPID METABOLISM; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASCULARIZATION;

3-HYDROXYBUTYRIC ACID; AGED; BLOOD GLUCOSE; CITRIC ACID; CROSS-OVER STUDIES; CYCLIC GMP; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FATTY ACIDS, NONESTERIFIED; FOREARM; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOCARDIAL ISCHEMIA; OXIDATION-REDUCTION; TRIMETAZIDINE;

EID: 33644878025     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00083.2005     Document Type: Article

References (39)

1. Bonadonna R, Groop LC, and Zych K. Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans. Am J Physiol Endocrinol Metab 259: E736-E750, 1990.
2. Brehm BR, Klaussner M, and Wolf SC. Chronic elevated endothelin-1 concentrations regulate mitogen-activated protein kinases ERK 1 and ERK 2 in vascular smooth muscle cells. Clin Sci (Colch) 48: 137S-1340S, 2002.
3. Cardillo C, Campia U, Bryant MB, and Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106: 1783-1788, 2002.
4. Cardillo C, Nambi SS, Kilcoyne CM, Choucair WK, Katz A, Quon MJ, and Panza JA. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 100: 820-825, 1999.
5. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, and Mandarino LJ. Insulin resistance differentially affects the PI3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105: 311-320, 2000.
6. Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arrhenius T, Harmon C, Yang G, Nadzan AM, and Lopaschuk GD. Malonyl coenzyme A decarboxylase inhibition protects the ischemic heart by ihnibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94: e78-e84, 2004.
7. El-Kady T, El-Sabban K, Gabaly M, Sabry A, and Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovsc Drugs 5: 271-278, 2005.
8. Eringa EC, Stehouwer CDA, Merlijn T, Westerhof N, and Sipkema P. Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovasc Res 56: 464-471, 2002.
9. Etgen GJ, Fryburg DA, and Gibbs EM. Nitric oxide stimulates skeletal muscle glucose transport through a calcium/contraction and phosphatidyl inositol-3-kinase-independent pathway. Diabetes 46: 1915-1919, 1997.
10. Fantini E, Demaison L, Sentex E, Grynberg A, and Athias P. Some biochemical aspects of the protective effects of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 26: 949-958, 1994.
11. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, and Margonato A. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 146: E18, 2003.
12. Groop L, Bonadonna R, and Shank M. Role of free fatty acids and insulin in determining free fatty acids and lipid oxidation in man. J Clin Invest 87: 83-89, 1991.
13. Harpey C, Clauser P, Labrid C, and Vaudry M. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev 6: 292-312, 1989.
14. Hatch GM, Smith AJ, Xu FY, Hall AM, and Bernlohr DA. FATP1 channels exogenous FA into 1,2,3-triacyl-sn-glycerol and down regulates sphingomyelin and cholesterol metabolism in growing 293 cells. J Lipid Res 43: 1380-1389, 2002.
15. Kantor PF, Lucien A, Kozak R, and Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86: 580-588, 2000.
16. Lee L, Horowitz J, and Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 25: 634-641, 2004.
17. Lewis GF, Carpentier A, Adeli K, and Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23: 201-229, 2002.
18. Lopaschuk GD, Barr R, Thomas PD, and Dyck JRB. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93: e33-e37, 2003.
19. Monti LD, Landoni C, Setola E, Galluccio E, Lucotti P, Sandoli EP, Origgi A, Lucignani G, Piatti P, and Fazio F. Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in type 2 diabetic patients. Am J Physiol Heart Circ Physiol 287: H1225-H1231, 2004.
20. Monti LD, Allibardi S, Piatti PM, Valsecchi G, Costa S, Pozza G, Chierchia S, and Samaja M. Triglycerides impair postischemic recovery in isolated hearts: roles of endothelin-1 and trimetazidine. Am J Physiol Heart Circ Physiol 281: H1122-H1130, 2001.
21. Napoli R, Guardasole V, Matarazzo M, Palmieri OlivieroU EA, Fazio S, and Saccà L. Growth hormone coirrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 39: 90-95, 2002.
22. Nuutila P, Knuuti MJ, Raitakari M, Ruotsalainen U, Teras M, Voipio-Pulkki LM, Haaparanta M, Solin O, Wegelius U,. and Yki-Jarvinen H. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans Am J Physiol Endocrinol Metab 267: E941-E946, 1994.
23. Piatti PM, Monti LD, Davis SN, Conti M, Brown MD, Pozza G, and Alberti KG. Effects of an acute decrease in non-esteried fatty acids levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients. Diabetologia 39: 103-112, 1996.
24. Piatti PM, Monti LD, Pacchioni M, Pontiroli AE, and Pozza G. Forearm insulin- and non-insulin-mediated glucose uptake and muscle metabolism in men: role of free fatty acids and blood glucose levels. Metabolism 40: 926-933, 1991.
25. Piatti P, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo A, Setola E, Lucotti P, Galluccio E, Ronchi C, Origgi A, Zavaroni I, Margonato A, and Colombo A. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 108: 2074-2081, 2003.
26. Piatti PM, Monti LD, Valsecchi G, Magni F, Setola E, Marchesi F, Galli-Kienle M, Pozza G, and Alberti KG. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 24: 875-880, 2001.
27. Piatti PM, Fragasso G, Monti LD, Setola E, Lucotti P, Fermo I, Paroni R, Galluccio E, Pozza G, Chierchia S, and Margonato A. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with ADMA levels. Circulation 107: 429-436, 2003.
28. Reaven GM. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
29. Stanley WC, Lopaschuk GD, Hall JL, and McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions. Cardiovasc Res 33: 243-257, 1997.
30. Stanley WC and Marzilli M. Metabolic therapy in the treatment of ischemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol 17: 133-145, 2003.
31. Steinberg HO and Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 45: 623-634, 2002.
32. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, and Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97: 2601-2610, 1996.
33. Trovati MP, Massucco P, Mattiello L, Cavalot F, Mularoni E, Hahn A, and Anfossi G. Insulin increases cyclic nucleotide content in human vascular smooth muscle cells: a mechanism potentially involved in insulin-induced modulation of vascular tone. Diabetologia 38: 936-941, 1995.
34. Vaag AA and Beck-Nielsen H. Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus. Acta Endocrinol 127: 344-350, 1992.
35. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M, and Rosano GM. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 25: 1814-1821, 2004.
36. Wilkes JJ, Hevener A, and Olefsky J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes 52: 1904-1909, 2003.
37. Young ME, Radda GK, and Leighton B. Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem J 322: 223-228, 1997.
38. Young ME, McNulty P, and Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes, part II: potential mechanisms. Circulation 105: 1861-1870, 2002.
39. Zhang S, Yang Y, Kone BC, Allen JC, and Kahn AM. Insulin-stimulated cyclic guanosine monophosphate inhibits vascular smooth muscle cell migration by inhibiting Ca/calmodulin-dependent protein kinase II. Circulation 107: 1539-1544, 2003.